Retrospective Cohort Study
Copyright ©The Author(s) 2025.
World J Gastroenterol. Jun 7, 2025; 31(21): 106939
Published online Jun 7, 2025. doi: 10.3748/wjg.v31.i21.106939
Figure 4
Figure 4 Sensitivity analysis of progression-free survival. A: After propensity score-matching analysis in progression-free survival (PFS) (ratio = 1); B: After propensity score-matching analysis in PFS (ratio = 2); C: After propensity score-matching analysis in PFS (ratio = 3); D: After inverse probability of treatment weighting analysis; E: Kaplan-Meier curve after excluding 4 patients who received single-agent chemotherapy combined with bevacizumab and anti- programmed death 1 immunotherapy in PFS; F: Kaplan-Meier curve restricting the cohort to irinotecan-based chemotherapy patients in PFS.